Will Ildong sell Nexium with annual sales of 50 billion won?

Ildong is likely to be a new partner

Strengthen cooperation with AZ

Daewoong and AstraZeneca will terminate a joint sales contract for Nexium, a PPI-based gastroesophageal reflux disease treatment.

 

The new joint sales partner of the large item, which generated about 50 billion won in sales last year, is said to be likely to be Ildong.

 

According to the pharmaceutical industry on the 9th, Daewoong and AstraZeneca agreed to terminate the joint sales contract of Nexium last month.

 

The contract is until December 31 this year.

 

Nexium is a PPI-based gastroesophageal reflux disease treatment launched in Korea in 2000.

 

Daewoong has been jointly selling with AstraZeneca since 2008.

 

Sales have steadily increased over the next 14 years, making it the No.

 

1 item in the same ingredient market.

 

According to the two companies, Nexium's sales reached 49.4 billion won last year.

 

Instead of breaking up with Nexium, Daewoong plans to focus on sales and marketing of Fexuprazan, which is expected to be released next year.

 

Daewoong is developing Fexuprazan, a P-CAB-based gastroesophageal reflux disease treatment.

 

It is a drug of the same family as K-CAB of HK inno.N, which is rapidly growing in the market.

 

Phase 3 clinical trials in 2019 have been completed.

 

Currently, it has applied for item permission from the MFDS.

 

It is also expected to be available as early as the end of this year.

 

Daewoong Pharmaceutical has already been approved for generics with components such as Nexium in 2019.

 

Starting next year, it is expected to sell Nexierd containing esomephrazole along with Fexuprazan.

 

Ildong is said to be the most likely new co-selling partner of Nexium.

 

Ildong is already jointly selling diabetes treatments such as Onglyza, Kombiglyze, and Qtern with AstraZeneca.

 

On top of that, it is expected to further strengthen the combined front with AstraZeneca by jointly selling Nexus from next year.

 

An official from Daewoong said, "The joint sales contract of Nexium will end at the end of this year," adding, "We decided not to extend the contract to focus on Fexuprazan, which is expected to be released next year." An official from the pharmaceutical industry said, "As far as I know, Ildong is likely to be the new partner of AstraZeneca, which will jointly sell Nexium," adding, "Unless there is a major change, the contract is expected to be signed soon."